{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:12:24Z","timestamp":1776244344027,"version":"3.50.1"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This CME\/CE integrates real patient stories, current evidence, evolving guideline recommendations, and expert clinical experience to equip hematology\/oncology clinicians with practical strategies for successful asparaginase\u2010based therapy in young adults with acute lymphoblastic leukemia (ALL). The overarching goal is to improve outcomes for young adults with ALL through more consistent application of pediatric\u2010inspired regimens, optimized asparaginase use, and comprehensive, patient\u2010centered care. Leukemia experts synthesize the latest evidence on the efficacy and safety of asparaginase\u2010based ALL treatment for young adults. Using a case\u2010based approach, the curriculum provides structured guidance on mitigation, monitoring, and management of key asparaginase\u2010related toxicities. Practical recommendations include therapeutic drug monitoring of asparaginase activity, detection of clinical and silent hypersensitivity reactions, and timely substitution of\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    \u2013derived asparaginase with\n                    <jats:italic>Erwinia<\/jats:italic>\n                    \u2010derived asparaginase to preserve therapeutic activity and efficacy after immune\u2010mediated inactivation. Beyond treatment selection and toxicity management, the activity addresses system\u2010level and psychosocial barriers that uniquely affect young adults with ALL, such as distance from specialty centers, employment and family responsibilities, lower rates of clinical trial participation, and survivorship concerns. To view this activity, and obtain CME\/CE credit, visit\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.cmeologyce.org\/ajh-all\">www.cmeologyce.org\/ajh\u2010all<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1002\/ajh.70195","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:31:25Z","timestamp":1768386685000},"page":"937-938","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients First: Navigating Asparaginase\u2010Based Treatment in Young Adults With Acute Lymphoblastic Leukemia"],"prefix":"10.1002","volume":"101","author":[{"given":"Ryan D.","family":"Cassaday","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology University of Washington School of Medicine  Seattle Washington USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Division of Leukemia Institute Physician, Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,14]]},"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:36:13Z","timestamp":1776242173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/ajh.70195"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70195","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"2025-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}